Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Subcutaneous Formulations of AZD6234 in Overweight or Obese Participants
NCT07220954Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenbelintide in obesity (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration, Area under the concentration-time curve from time 0 to the time of the last measurable concentration and 1 more. Started Nov 2025; status: completed.
02
Drugs
lenbelintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07220954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07220954.